Clinical Bioenergetics

<p>Part I: Foundational aspects of bioenergetics and disease<br>1. Tissue specificity of energy metabolism in mitochondria<br>2. Impaired mitochondrial bioenergetics and signaling pathways: an overview</p> <p>Part II: Disease-specific case studies<br>3. Abnormal mitochondrial metabolism in obesity and insulin resistance<br>4. Impaired mitochondrial energy metabolism: etiologies and implications in neurodegenerative disease<br>5. Mitochondrial dysfunction in kidney diseases<br>6. Mitochondrial role in NAFLD as a chronic disease<br>7. Decreased bioenergetics in traumatic brain injury<br>8. Impaired mitochondrial bioenergetics in psychiatric disorders</p> <p>Part III: Modes of analysis in clinical bioenergetics<br>9. Monitoring mitochondrial oxygenation in clinical environment<br>10. Assessing metabolic flexibility and mitochondrial bioenergetics<br>11. Assessing the real-time metabolism and bioenergetics of single cells using fluorescence biosensors<br>12. Bioenergetic profiling in the skin<br>13. Evaluating tissue bioenergetics by phosphorous-31 magnetic resonance spectroscopy<br>14. Targeting respiratory complex Idmolecular mechanism and drug design</p> <p>Part IV: Theraputic opportunities for impaired bioenergetics<br>15. Targeting Alzheimer’s disease neuronal mitochondria as a therapeutic approach<br>16. Mitochondria replacement as an innovative treatment to tackle impaired bioenergetics in clinical medicine<br>17. Mitochondrial drug delivery systems: therapeutic application for clinical bioenergetics in neurodegenerative disease<br>18. Dietary interventions for patients with obesity and impaired bioenergetics<br>19. Novel nutraceuticals to tackle brain and muscle bioenergetics<br>20. Therapeutic targeting of cardiolipin composition in injury and disease using TPP-conjugated compounds<br>21. NEET proteins as novel drug targets for mitochondrial dysfunction<br>22. Translation of bioenergetics therapies: challenges from bench to bedside<br>23. New therapeutics to modulate mitochondrial energy metabolism in neurodegenerative disorders: the example of mitochondrial disorders<br>24. Targeting impaired bioenergetics in heart failure<br>25. Exploring vulnerabilities of quiescent tumor cells by targeting mitochondrial bioenergetics<br>26. Modulation of the mitochondrial function with polyphenols and other natural bioactive compounds to treat obesity<br>27. Antioxidants and natural-derived products in the modulation of mitochondrial bioenergetics and dysfunction in chronic kidney disease models<br>28. Transcranial and systemic photobiomodulation for the enhancement of mitochondrial metabolism in depression<br>29. Alterations in mitochondrial glucose carbon metabolism in epilepsy and targeted metabolic treatments</p>